Last reviewed · How we verify

Topical IBU twice daily — Competitive Intelligence Brief

Topical IBU twice daily (Topical IBU twice daily) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID. Area: Pain Management.

phase 3 NSAID Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Topical IBU twice daily (Topical IBU twice daily) — Pfizer. Topical IBU works by reducing pain and inflammation at the site of application.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Topical IBU twice daily TARGET Topical IBU twice daily Pfizer phase 3 NSAID
Cytotec Misoprostol Pfizer marketed NSAID combined with prostaglandin analog Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors 1988-01-01
Aleve naproxen Generic (originally Syntex) marketed NSAID Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3, Prostaglandin G/H synthase 1 1976-01-01
Aspirin acetylsalicylic acid Bayer AG marketed NSAID, Antiplatelet agent Gamma-glutamyltranspeptidase 1, Nicotinate phosphoribosyltransferase, Acid-sensing ion channel 3 1899-03-06
Surgery with Naproxen Surgery with Naproxen Giovana Maria Weckwerth marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2)
Rectal Indomethacin Rectal Indomethacin Moti Lal Nehru Medical College marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
lysine acetylsalicylate lysine acetylsalicylate Azienda Ospedaliera San Giovanni Battista marketed Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID class)

  1. Antibe Therapeutics Inc. · 3 drugs in this class
  2. Iroko Pharmaceuticals, LLC · 3 drugs in this class
  3. Organon and Co · 2 drugs in this class
  4. Apsen Farmaceutica S.A. · 2 drugs in this class
  5. Amneal Pharmaceuticals, LLC · 2 drugs in this class
  6. Behar, Caren, M.D. · 2 drugs in this class
  7. IDEA AG · 2 drugs in this class
  8. Noven Pharmaceuticals, Inc. · 2 drugs in this class
  9. HALEON · 2 drugs in this class
  10. Pfizer · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Topical IBU twice daily — Competitive Intelligence Brief. https://druglandscape.com/ci/topical-ibu-twice-daily. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: